Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.
J Antimicrob Chemother
December 2024
Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
Background: Carbapenem-resistant Gram-negative bacteria (CR-GNB) develop resistance to many antimicrobials. To effectively manage infections caused by these organisms, novel agents and/or combinations of antimicrobials are required.
Objectives: Evaluated the in vitro efficacy of ceftazidime/avibactam in combination with other antimicrobials against CR-GNB.
Improved synthesis and evaluation of preclinical pharmacodynamic parameters of a new monocyclic β-lactam DPI-2016.
Bioorg Med Chem Lett
February 2024
Ningxia Centre of Organic Synthesis and Engineering Technology, Ningxia Academy of Agriculture and Forestry Sciences, No. 590, Huanghe East Road, Jinfeng District, Yinchuan, Ningxia 750002, PR China. Electronic address:
Monocyclic β-lactams are stable to a number of β-lactamases and are the focus of researchers for the development of antibacterial drugs, particularly against Enterobacterales. We recently synthesized and reported the bactericidal activity of diverse series of aztreonam appended with amidine moieties as siderophores. One of the derivatives exhibiting the highest MIC value in vitro was selected for further preclinical studies.
View Article and Find Full Text PDFMachine Learning-Led Optimization of Combination Therapy: Confronting the Public Health Threat of Extensively Drug Resistant Gram-Negative Bacteria.
Clin Pharmacol Ther
April 2024
School of Pharmacy & Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
Article Synopsis
- - This study presents a new method using hybrid machine-learning techniques to optimize combination antibiotic therapies by analyzing human and in vitro data together.
- - Researchers focused on three antibiotics—aztreonam, ceftazidime/avibactam, and polymyxin B—using a genetic algorithm to create effective treatment regimens while balancing efficacy and toxicity.
- - The findings demonstrated that machine-learning optimization could produce effective dosage regimens for treating drug-resistant Klebsiella pneumoniae infections, offering a fresh perspective on antibiotic treatment strategies.
Successful Treatment of Persistent Bacteremia With Cefiderocol in an Infant.
Open Forum Infect Dis
April 2023
Johns Hopkins University School of Medicine, Department of Pediatrics, Baltimore, Maryland, USA.
is an important nosocomial pathogen with limited treatment options. Trimethoprim-sulfamethoxazole (TMP-SMX) is generally regarded as the preferred therapy; however, treatment failures with TMP-SMX have been reported. Herein, we report a case of a 5-week-old infant with 8 days of bacteremia while receiving TMP-SMX, despite in vitro susceptibility.
View Article and Find Full Text PDFEvaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales.
Microbiol Spectr
December 2022
Microbiologics Antibiotic and Microbiome Research Center, Kalamazoo, Michigan, USA.
As multidrug and pan-resistance among Enterobacterales continue to increase, there is an urgent need for more therapeutic options to treat these infections. New β-lactam and β-lactam inhibitor (BLI) combinations have a broad spectrum of activity, but those currently approved do not provide coverage against isolates harboring metallo-β-lactamases (MBL). Aztreonam (ATM) and avibactam (AVI) in combination (ATM/AVI; AVI at 4 μg/mL fixed concentration) provides a similarly broad range of activity while maintaining activity against MBL-producing isolates.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!